Dr Rachel Giles guides us through 6 abstracts from the European Charcot Foundation 28th Annual Meeting:
- No association between Ig levels and infection in ofatumumab-treated patients - Wiendl et al.
- First long-term efficacy data of a BTK inhibitor - Montalban et al.
- Reliable and convenient method to assess cognitive function in MS patients - Miyazaki et al.
- Real-world efficacy of ocrelizumab in MS patients - Eggebrecht et al.
- Long-term safety and efficacy of ozanimod in relapsing MS - Selmaj et al.
- Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes - Kappos et al.
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Characteristics of a population-based MS cohort treated with DMDs Next Article
Tackling unmet MS-related cognitive challenges »
« Characteristics of a population-based MS cohort treated with DMDs Next Article
Tackling unmet MS-related cognitive challenges »
Related Articles
December 16, 2020
Real-world efficacy of ocrelizumab in MS patients
December 16, 2020
Defining phenotypes of MS-related cognitive impairment
December 16, 2020
First long-term efficacy data of a BTK inhibitor
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy